Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Early antiretroviral treatment may preserve key immune responses to HIV

Investigators from the Ragon Institute of MGH, MIT and Harvard have found that instituting combination antiretroviral treatment at the earliest stages of HIV infection may allow the generation of functional CD8 'killer' T cells and preservation of the CD4 helper T cells that are the virus's primary target.

Published
23 May 2019
From
Eurekalert Inf Dis
Aging HIV population face complicated rheumatologic care

As the national population of patients who are HIV-positive continues to age, rheumatologists will be increasingly called on to manage routine care for crystal disease, osteoarthritis, soft tissue rheumatism and other conditions, according to Leonard Calabrese, DO, of the Cleveland Clinic.

Published
22 May 2019
From
Healio
Many Women on HIV Treatment Are at Risk of Developing a Detectable Viral Load

An ongoing study finds that considerable challenges in such women’s lives may compromise their adherence to antiretrovirals.

Published
22 May 2019
From
Poz
Medicare decides against tighter management of HIV drugs

The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

Published
21 May 2019
From
BioPharma Dive
One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

One in 3 people in a 286-person French HIV group took illicit drugs that sometimes posed a risk of severe interactions with antiretrovirals. Many potential interactions involved the boosting agents ritonavir or cobicistat.

Published
17 May 2019
From
NATAP
CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA

After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA. Trial will include 10 weeks of induction therapy to identify which patients are likely to respond and which patients can safely return to their original HAART regimen.

Published
17 May 2019
From
CytoDyn press release
Analytical treatment interruptions: minimising the risks and maximising their scientific value

Recommendations for the safe and appropriate use of ‘analytical treatment interruptions’ have been developed by a group of HIV experts, including clinicians, patient advocates, bioethicists, social scientists and

Published
15 May 2019
By
Alain Volny-Anne
Some people may have genes that hamper a drug's HIV protection

Some people’s genes may stop an antiretroviral drug from protecting them against HIV, a genetics study suggests.

Published
13 May 2019
From
Science News
NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

Published
09 May 2019
From
National Institute of Allergy and Infectious Diseases
Russia wants to make HIV/Aids denialism illegal to halt epidemic

Denialists have been gaining attention in country where treatment rates are already low.

Published
07 May 2019
From
The Guardian
← First12345...503Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.